Garber Alan M — SEC insider filings
SEC reporting owner CIK 1312907. 16 insider filings on record with FilingPulse; latest filed 2026-10-19.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2021-03-17 to 2026-10-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 4 legs across 4 filings — 120,506 shares, $2,552,033 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 23.
- Largest priced transaction: sale of 40,000 shares @ $23.60 ($944,000) in EXELIXIS, INC., filed 2021-03-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| EXELIXIS, INC. (EXEL) | Director | 7 | — | 4 legs · 120,506 sh · $2,552,033 | 11 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | Director | 9 | — | — | 12 |
Insider filings — Garber Alan M
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-19 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 29.27 (derivative) @ $512.44 | EDGAR |
| 2026-07-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 31.56 (derivative) @ $475.28 | EDGAR |
| 2026-05-05 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 472 @ $0 · Grant/award (A): 1,433 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 33.90 (derivative) @ $442.50 | EDGAR |
| 2025-05-05 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 398 @ $0 · Grant/award (A): 1,199 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 3,142 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | EXELIXIS, INC. (EXEL) | Option exercise (M): 23,491 @ $19.57 · Sale (S): 19,205 @ $24.01 · Option exercise (M): 23,491 (derivative) @ $0 | EDGAR |
| 2023-06-02 | 4 | EXELIXIS, INC. (EXEL) | Grant/award (A): 44,087 (derivative) @ $0 | EDGAR |
| 2023-05-03 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 584 @ $0 · Grant/award (A): 1,741 (derivative) @ $0 | EDGAR |
| 2023-02-23 | 4 | EXELIXIS, INC. (EXEL) | Option exercise (M): 40,000 @ $6.30 · Sale (S): 40,000 @ $17.49 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2022-05-27 | 4 | EXELIXIS, INC. (EXEL) | Grant/award (A): 42,422 (derivative) @ $0 | EDGAR |
| 2022-05-03 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 4,462 (derivative) @ $0 | EDGAR |
| 2022-03-03 | 4 | EXELIXIS, INC. (EXEL) | Option exercise (M): 40,000 @ $3.13 · Sale (S): 21,301 @ $21 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2021-05-28 | 4 | EXELIXIS, INC. (EXEL) | Grant/award (A): 33,549 (derivative) @ $0 | EDGAR |
| 2021-05-04 | 4 | VERTEX PHARMACEUTICALS INC / MA (VRTX) | Grant/award (A): 6,067 (derivative) @ $0 | EDGAR |
| 2021-03-17 | 4 | EXELIXIS, INC. (EXEL) | Option exercise (M): 40,000 @ $3.38 · Sale (S): 40,000 @ $23.60 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-03-15 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1312907 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs